A Short History of Data Banking in the United States from 1974 to 2003

Journal of Rheumatology

Volumn 31, Issue SUPPL. 69, 2004, Pages 41-45

  Wolfe, Frederick ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

Author keywords

Aramis; Data banks; National Data Bank for rheumatic diseases; Rheumatology

Indexed keywords

CONFERENCE PAPER; DATA BASE; HEALTH SURVEY; HISTORY; HUMAN; LANGUAGE; LONGITUDINAL STUDY; MEDICAL DOCUMENTATION; MEDICAL RECORD; MEDICAL SPECIALIST; METHODOLOGY; MODEL; PRIORITY JOURNAL; RHEUMATOLOGY; UNITED STATES; NOMENCLATURE; REVIEW; RHEUMATOID ARTHRITIS; STANDARD; STATISTICS;

ARTHRITIS, RHEUMATOID; DATABASES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; RHEUMATOLOGY; TERMINOLOGY; UNITED STATES;

EID: 3042622269     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (84)

1. Fries JF, Hess EV, Klinenberg J. A standard database for rheumatic diseases. Arthritis Rheum 1974;17:327-36.
2. Fries JF. A data bank for the clinician? [editorial]. N Engl J Med 1976;294:1400-2.
3. Weyl S, Fries J, Wiederhold G, Germano F. A modular self-describing clinical databank system. Comput Biomed Res 1975;8:279-93.
4. Fries JF. Alternatives in medical record formats. Med Care 1974;12:871-81.
5. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis and causes of death in rheumatoid arthritis. Arthritis Rheum 1986;29:706-14.
6. Mitchell DM, Fries JF. An analysis of the American Rheumatism Association criteria for rheumatoid arthritis. Arthritis Rheum 1982;25:481-7.
7. Fries JF, Mitchell DM. Joint pain or arthritis. JAMA 1976;235:199-204.
8. Levinson JE. The ideal program for juvenile arthritis. Arthritis Rheum 1977;20 Suppl:607-10.
9. Steen VD, Blair S, Medsger TA Jr. The toxicity of D-penicillamine in systemic sclerosis. Ann Intern Med 1986;104:699-705.
10. Steen VD, Medsger TA Jr, Rodnan GP. D-penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982;97:652-9.
11. Masi AT, Rodnan GP, Medsger TA Jr, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
12. Felson DT. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis: Comment - Reply. Arthritis Rheum 1996;39:536-7.
13. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
14. Wolfe F, Fries JF. ARAMIS today: moving toward internationally distributed databank systems for follow-up studies. Clin Rheumatol 1987;6 Suppl 2:93-102.
15. Fries JF. The chronic disease data bank: first principles to future directions. J Med Philos 1984;9:161-80.
16. Pincus T, Wolfe F. Treatment of rheumatoid arthritis: challenges to traditional paradigms [editorial]. Ann Intern Med 1991;115:825-7.
17. Pincus T, Brooks RH, Callahan LF. Reliability of grip strength, walking time and button test performed according to a standard protocol. J Rheumatol 1991;18:997-1000.
18. Callahan LF, Pincus T. Associations between clinical status questionnaire scores and formal education level in persons with systemic lupus erythematosus. Arthritis Rheum 1990;33:407-11.
19. Callahan LF, Smith WJ, Pincus T. Self report questionnaires in five rheumatic diseases: Comparisons of health status constructs and associations with formal education level. Arthritis Care Res 1989;2:122-31.
20. Fuchs HA, Brooks RH, Callahan LF, Pincus T. A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum 1989;32:531-7.
21. Pincus T, Callahan LF. Clinical use of multiple nonsteroidal antiinflammatory drug preparations within individual rheumatology private practices. J Rheumatol 1989;16:1253-8.
22. Pincus T, Callahan LF, Brooks RH, Fuchs HA, Olsen NJ, Kaye JJ. Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Ann Intern Med 1989;110:259-66.
23. Brooks RH, Callahan LF, Pincus T. Use of self-report activities of daily living questionnaires in osteoarthritis. Arthritis Care Res 1988;1:23-32.
24. Callahan LF, Brooks RH, Pincus T. Further analysis of learned helplessness in rheumatoid arthritis using a Rheumatology Attitudes Index. J Rheumatol 1988;15:418-26.
25. Fuchs HA, Callahan LF, Kaye JJ, Brooks RH, Nance EP, Pincus T. Radiographic and joint count findings of the hand in rheumatoid arthritis. Related and unrelated findings. Arthritis Rheum 1988;31:44-51.
26. Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988;41:1037-41.
27. Pincus T, Callahan LF, Vaughn WK. Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. J Rheumatol 1987;14:240-51.
28. Pincus T, Callahan LF. Formal education as a marker for increased mortality and morbidity in rheumatoid arthritis. J Chron Dis 1985;38:973-84.
29. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
30. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53.
31. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate therapy and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
32. Wolfe F, van der Heijde DM, Larsen A. Assessing radiographic status of rheumatoid arthritis: introduction of a short erosion scale. J Rheumatol 2000;27:2090-9.
33. Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: A prospective 13 year study of 2131 patients. J Rheumatol 2000;27:1668-73.
34. Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1072-82.
35. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: A 19-year study of radiographic progression. Arthritis Rheum 1998;41:1571-82.
36. Wolfe F, Hawley DJ. The long-term outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients. J Rheumatol 1998;25:2108-17.
37. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997;24:1477-85.
38. Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br J Rheumatol 1997;36:786-93.
39. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407-17.
40. Wolfe F, Michaud K. The clinical and research significance of the erythrocyte sedimentation rate. J Rheumatol 1994;21:1227-37.
41. Wolfe F, Hawley DJ, Cathey MA. Measurement of gold treatment effect in clinical practice: evidence for effectiveness of intramuscular gold therapy. J Rheumatol 1993;20:797-802.
42. Wolfe F, Hawley DJ. The relationship between clinical activity and depression on rheumatoid arthritis. J Rheumatol 1993;20:2032-7.
43. Sharp JT, Wolfe F, Mitchell DM, Bloch DA. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first 25 years of disease. Arthritis Rheum 1991;34:660-8.
44. Wolfe F, Cathey MA. Analysis of methotrexate treatment effect in a longitudinal observational study: utility of cluster analysis. J Rheumatol 1991;18:672-7.
45. Wolfe F, Cathey MA, Hawley DJ. Improvement in gold treated rheumatoid arthritis patients: a second look at gold effectiveness in the community [abstract]. Arthritis Rheum 1991;34 Suppl:S53.
46. Wolfe F, Hawley DJ, Cathey MA. The assessment and prediction of functional disability in RA. J Rheumatol 1991;18:1298-306.
47. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
48. Wolfe F, Kleinheksel SM, Khan MA. Familial vs sporadic rheumatoid arthritis: a comparison of the demographic and clinical characteristics of 956 patients. J Rheumatol 1988;15:400-4.
49. Wolfe F, Cathey MA. The epidemiology of tender points: A prospective study of 1520 patients. J Rheumatol 1985;12:1164-8.
50. Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. J Rheumatol 1985;12:245-52.
51. Wolfe F, Cathey MA, Kleinheksel SM, et al. Psychological status in primary fibrositis and fibrositis associated with rheumatoid arthritis. J Rheumatol 1984;11:500-6.
52. Wolfe F, Cathey MA. Prevalence of primary and secondary fibrositis. J Rheumatol 1983;10:965-8.
53. Albert DA, Aksentijevich S, Hurst S, Fries JF, Wolfe F. Modeling therapeutic strategies in rheumatoid arthritis: Use of decision analysis and Markov models. J Rheumatol 2000;27:644-52.
54. Williams CA, Bloch DA, Sibley J, et al. Lymphoma and leukemia in rheumatoid arthritis: are they associated with azathioprine, cyclophosphamide, or methotrexate? A matched case-control study in the Arthritis, Rheumatism and Aging Medical Information System (ARAMIS) population. J Clin Rheumatol 1996;2:64-72.
55. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
56. Michel BA, Bloch DA, Wolfe F, Fries JF. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 1993;20:1666-9.
57. Sherrer YS, Bloch DA, Mitchell DM, Roth SH, Wolfe F, Fries JF. Disability in rheumatoid arthritis: comparison of prognostic factors across three populations. J Rheumatol 1987;14:705-9.
58. Fries JF, Spitz PW, Mitchell DM, Roth SH, Wolfe F, Bloch DA. Impact of specific therapy upon rheumatoid arthritis. Arthritis Rheum 1986;29:620-7.
59. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986;29:488-93.
60. Wolfe F, Kleinheksel SM, Spitz PW, et al. A multicenter study of hospitalization in rheumatoid arthritis. Frequency, medical-surgical admissions, and charges. Arthritis Rheum 1986;29:614-9.
61. Wolfe F, Kleinheksel SM, Spitz PW, et al. A multicenter study of hospitalization in rheumatoid arthritis: effect of health care system, severity, and regional difference. J Rheumatol 1986;13:277-84.
62. Paulus HE, Wiesner J, Bulpitt KJ, et al. Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment. J Rheumatol 2002;29:2513-20.
63. Newhall-Perry K, Law NJ, Ramos B, et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. J Rheumatol 2000;27:1156-63.
64. Paulus HE, Bulpitt KJ, Ramos B, Park G, Wong WK. Relative contributions of the components of the American College of Rheumatology 20% criteria for improvement to responder status in patients with early seropositive rheumatoid arthritis. Arthritis Rheum 2000;43:2743-50.
65. Munster T, Paulus HE, Clements PJ, Bulpitt KJ, Wong WK, Furst DE, Western Consortium of Practicing Rheumatologists. Abbreviated joint counts are as sensitive as more complete joint counts when testing response using ACR response criteria (ACR 20 and ACR 50) [abstract]. Arthritis Rheum 1999;42 Suppl:1670.
66. Paulus HE, Ramos B, Wong WK, et al. Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the Disease Activity Score in patients with early rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. J Rheumatol 1999;26:2324-31.
67. Wong AL, Wong WK, Harker J, et al. Patient self-report tender and swollen joint counts in early rheumatoid arthritis. J Rheumatol 1999;26:2551-61.
68. Berkanovic E, Oster P, Wong WK, et al. The relationship between socioeconomic status and recently diagnosed rheumatoid arthritis. Arthritis Care Res 1996;9:257-62.
69. Fries JF, Wolfe F, Apple R, et al. HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum 2002;46:2320-9.
70. Wolfe F, Pincus T, Fries JF. Use of second line "disease modifying" anti-rheumatic drugs (DMARDs) within 5 months of disease onset by 64% of 750 rheumatoid arthritis patients under the care of 142 US rheumatologists: an inception cohort study [abstract]. Arthritis Rheum 1997;40 Suppl:S218.
71. Wolfe F, Flowers N, Anderson J. The National Rheumatic Disease Data Bank: case mix and severity characteristics of patients in rheumatological practice [abstract]. Arthritis Rheum 1998;41 Suppl:S132.
72. Wolfe F. Pain extent and diagnosis: development and validation of the Regional Pain Scale in 12,799 patients with rheumatic disease. J Rheumatol 2003;30:369-78.
73. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003;30:36-40.
74. Ethgen O, Kahler KH, Kong SX, Reginster JY, Wolfe F. The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis. J Rheumatol 2002;29:1147-55.
75. Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002;29:467-73.
76. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002;29:1015-22.
77. Wolfe F. The psychometrics of functional status questionnaires: room for improvement. J Rheumatol 2002;29:865-8.
78. Wolfe F, Pincus T, Tennant A. HAQ-II: Application of modern item response theory to the design of an improved HAQ questionnaire [abstract]. Ann Rheum Dis 2002;61:90.
79. Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2491 rheumatoid arthritis patients following leflunomide initiation. J Rheumatol 2001;28:982-9.
80. Wolfe F, Flowers N, Anderson J, Urbansky K. Tuberculosis rates are not increased in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2001;44 Suppl:S105.
81. Wolfe F, Choi HK. Benchmarking and the percentile assessment of RA: adding a new dimension to rheumatic disease measurement. Ann Rheum Dis 2001;60:994-5.
82. Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000;43:2751-61.
83. Wolfe F, Kong SX, Watson DJ. Gastrointestinal symptoms and health related quality of life in patients with arthritis. J Rheumatol 2000;27:1373-8.
84. Wolfe F. The importance of gastrointestinal (GI) symptom severity in rheumatoid and osteoarthritis: Symptom rates and risk for GI hospitalization. J Rheumatol 2000;27:1661-7.